Artificial Heart Market Size, Share and Growth Outlook, 2026

Artificial Heart Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Artificial Heart Market size is forecast to increase from $3.56 Billion in 2026 to $8.5 Billion in 2034 at a CAGR of 11.5% between 2026 and 2034.

The Artificial Heart market report provides detailed analysis and outlook of Artificial Heart segments including By Device Type (Ventricular Assist Devices, Total Artificial Hearts, Cardiopulmonary Bypass / Heart-Lung Machines), By Technology (Centrifugal Flow Pumps, Axial Flow Pumps, Pneumatic & Electromagnetic Systems), By Therapy (Bridge-to-Transplant, Destination Therapy, Bridge-to-Candidacy ), By Patient Group (Adult Patients, Pediatric Patients), By End-User (Hospitals & Transplant Centers, Specialized Cardiac & Medical Specialty Centers) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Artificial Heart Industry Overview

Innovation in Artificial Organ Technologies Supports Future Cardiovascular Solutions

The artificial heart industry continues to benefit from broader advancements in implantable medical technologies, miniaturized electronics, wireless systems, and artificial intelligence-driven healthcare innovations. As the demand for advanced solutions to address severe organ dysfunction grows, research institutions and technology developers are increasingly exploring next-generation implantable systems capable of improving patient outcomes and long-term quality of life. The integration of bioengineering, wireless communication technologies, and sophisticated monitoring capabilities is influencing the development of future artificial organ platforms, supporting progress toward more personalized and durable therapeutic solutions.

Wireless Implant Technologies Highlight the Potential of Advanced Medical Devices

A notable example of innovation in implantable healthcare technology is the advancement of the Intracortical Visual Prosthesis (ICVP) by researchers at the Illinois Institute of Technology. The successful third implantation of this wireless neuroprosthetic system demonstrated the growing capability of fully implantable medical devices utilizing miniaturized electronics and wireless communication networks. The technology employs Wireless Floating Microelectrode Arrays (WFMAs) to establish direct communication with the visual cortex while enabling permanent implantation. Although developed for visual restoration applications, the engineering principles behind wireless implantable systems, long-term device integration, and scalable neurotechnology platforms provide valuable insights that are increasingly relevant across the broader artificial organ and implantable medical device sectors. These advancements underscore the growing importance of miniaturization, wireless functionality, and long-term biocompatibility in future artificial organ development.

Artificial Intelligence and Clinical Outcome Assessment Support Device Evolution

The increasing use of artificial intelligence and digital health technologies is also influencing the future direction of advanced implantable devices. XPANCEO demonstrated industrial-ready smart contact lens prototypes that combine micro-displays, wireless power delivery, and integrated health-monitoring sensors. The company’s AI-powered glaucoma management lens, trained on 10,000 measurements, illustrates the growing role of predictive analytics, remote monitoring, and non-invasive healthcare technologies. Similar digital health principles are increasingly being explored across implantable device markets to improve patient monitoring and clinical decision-making. In parallel, clinical studies evaluating prosthetic device functionality continue to provide valuable insights into long-term patient outcomes. Research involving custom ocular prostheses identified strong correlations between device performance, duration of use, patient age, and quality of life metrics. Such outcome-based evaluation methodologies are increasingly important across artificial organ technologies, where functional performance, patient satisfaction, and long-term durability remain critical measures of clinical success.

Artificial Heart Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Artificial Heart market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Abiomed, Inc. (Johnson & Johnson MedTech), Abbott Laboratories, SynCardia Systems, LLC, Carmat SA, Medtronic plc, Berlin Heart GmbH, Jarvik Heart, Inc., Getinge AB (Maquet Cardiovascular), LivaNova PLC, Shenzhen Core Medical Technology. The Artificial Heart market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Artificial Heart industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Artificial Heart Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Artificial Heart companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Artificial Heart markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Artificial Heart Market Competitive Benchmarking and Company Analysis

Leading companies in Artificial Heart industry include- Abiomed, Inc. (Johnson & Johnson MedTech), Abbott Laboratories, SynCardia Systems, LLC, Carmat SA, Medtronic plc, Berlin Heart GmbH, Jarvik Heart, Inc., Getinge AB (Maquet Cardiovascular), LivaNova PLC, Shenzhen Core Medical Technology. The Artificial Heart market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Artificial Heart Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Artificial Heart market remains one of the strongest-performing segments in the country.
The US Artificial Heart Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Artificial Heart market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Artificial Heart industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Artificial Heart markets

Canada's strong Artificial Heart sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Artificial Heart market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Artificial Heart Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Artificial Heart market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Artificial Heart population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Artificial Heart industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Artificial Heart market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Artificial Heart sales through 2034

France Artificial Heart companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Artificial Heart Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Artificial Heart distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Artificial Heart Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Artificial Heart market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Artificial Heart industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Artificial Heart industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Artificial Heart Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Artificial Heart market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Artificial Heart market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Artificial Heart Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Artificial Heart Market Segmentation

By Device Type
Ventricular Assist Devices
Total Artificial Hearts
Cardiopulmonary Bypass / Heart-Lung Machines
By Technology
Centrifugal Flow Pumps
Axial Flow Pumps
Pneumatic & Electromagnetic Systems
By Therapy
Bridge-to-Transplant
Destination Therapy
Bridge-to-Candidacy
By Patient Group
Adult Patients
Pediatric Patients
By End-User
Hospitals & Transplant Centers
Specialized Cardiac & Medical Specialty Centers

Top Companies in Artificial Heart Industry

Abiomed, Inc. (Johnson & Johnson MedTech)
Abbott Laboratories
SynCardia Systems, LLC
Carmat SA
Medtronic plc
Berlin Heart GmbH
Jarvik Heart, Inc.
Getinge AB (Maquet Cardiovascular)
LivaNova PLC
Shenzhen Core Medical Technology

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa